Quick Answer
Contineum Therapeutics, Inc. reported Net Income of -$59.98 million for fiscal year 2025.
Contineum Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$59.98M | -41.9% |
| 2024 | -$42.26M | -286.0% |
| 2023 | $22.72M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.79M | -24.6% | +20.2% |
| June 30, 2025 | -$16.04M | -78.0% | -0.3% |
| March 31, 2025 | -$15.99M | -90.0% | -55.7% |
| September 30, 2024 | -$10.27M | -64.2% | -14.0% |
| June 30, 2024 | -$9.01M | -121.7% | -7.0% |
| March 31, 2024 | -$8.42M | -74.5% | -34.7% |
| September 30, 2023 | -$6.25M | — | -115.0% |
| June 30, 2023 | $41.56M | — | +961.6% |
- Contineum Therapeutics, Inc. showed a decrease of -41.9% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s net income has declined by 364.0% (from $22.72 million to -$59.98 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: